apigenin; ⌬F508 cystic fibrosis transmembrane conductance regulator; cystic fibrosis transmembrane conductance regulator knockout; glibenclamide; rectum; epithelia CYSTIC FIBROSIS (CF) is an autosomal recessively inherited disease caused by a mutation of the CF transmembrane conductance regulator (CFTR) gene, which encodes for the cAMP-regulated Cl Ϫ channel in the apical membranes of epithelial cells. Numerous CF-causing mutations of CFTR have been described. The most common mutation is a deletion of phenylalanine at position 508 of CFTR (⌬F508 CFTR) that is present on 66% of CF chromosomes; 88% of CF patients carry at least one ⌬F508 allele (32) . This mutation leads to a misfolded protein that is retained in the endoplasmic reticulum and is targeted for rapid degradation (5, 14, 37) . Epithelial cells homozygous for the ⌬F508 mutation have an extremely reduced plasma membrane Cl Ϫ conductance (25, 29, 35) . When ⌬F508 CFTR was overexpressed so that it could translocate to the cell membrane, ⌬F508 CFTR formed a functional Cl Ϫ channel with a reduced open probability (9, 11, 19 ) and a reduced half-life in the membrane (28) .
Currently, there is no treatment for CF that targets the molecular defect of CFTR. Possible targets for pharmacological interventions are 1) the CFTR channel in the membrane, 2) signaling cascades that regulate CFTR, and 3) the maturation and trafficking pathway of CFTR. A number of small, hydrophilic molecules have been recently introduced as chemical chaperones (3, 34) , which promoted protein folding and maturation. When 3T3 cells expressing ⌬F508 CFTR were treated with the chemical chaperone trimethylamine oxide (TMAO) at concentrations of 50-100 mM, fully glycosylated mature ⌬F508 CFTR was found and the Cl Ϫ permeability of the cell membrane was partially restored (3). This result suggested that treatment with TMAO was able to correct the processing defect of ⌬F508 CFTR. To test the effects of TMAO in vivo, Bai et al. (1) developed a treatment protocol for mice that resulted in serum concentrations of TMAO (50-100 mM) that were effective in cell culture models. The current study was designed to determine the in vivo efficacy of TMAO treatment for the correction of the cAMP-stimulated, Cl study. The mice were fed a standard diet. The mice were subcutaneously injected with TMAO from a 2 M stock solution in water (or with water as a negative control) every 8 h for 48 h. The mice were treated with 1-7 g/kg body wt. The highest dose used (7 g/kg body wt) resulted in ϳ50% deaths in wild-type mice, i.e., approximates the half-maximal lethal dose for TMAO as shown in a previous study by Bai et al. (1) . In CF mice, the highest dose used was 4 g/kg body wt. RPD was measured before treatment and 24 and 48 h after the start of treatment.
Measurement of RPD. RPD was measured with a protocol similar to that for nasal potential difference measurements in humans (21) . Mice were anesthetized with 1 l/g body wt of 0.4 mg/ml of acepromazine and 11 mg/ml of ketamine. RPD was sensed with a 1 M NaCl-agar bridge inserted ϳ2 cm into the rectum and connected through a Ag-AgCl electrode to a high-impedance (Ͼ1-G⍀) digital voltmeter. Readings were amplified and interfaced to a computer for continuous recording. Potentials were measured with respect to a subcutaneous, 1 M NaCl-filled needle. A second rectal tube was used for continuous perfusion of and drug administration into the rectum. Solutions were perfused by gravity flow at ϳ1 ml/ min at room temperature. The Cl Ϫ -containing solution had the following composition (in mM): 145 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 0.1 amiloride, pH 7.4. The Cl Ϫ -free solution contained (in mM) 145 sodium gluconate, 4 potassium gluconate, 4 calcium gluconate, 1 magnesium gluconate, 10 HEPES, and 0.1 amiloride, pH 7.4.
Drugs and chemicals. Forskolin (Calbiochem, La Jolla, CA) was used at 20 M from a 100 mM stock solution in dimethyl sulfoxide (DMSO). Amiloride was used at 100 M from a 10 mM stock solution in water. Glibenclamide was used at 300 M from a 100 mM stock solution in DMSO. Apigenin (4Ј,5,7-trihydroxyflavone) was used at 30 M from a 100 mM stock solution in DMSO. If not mentioned otherwise, chemicals were from Sigma (St. Louis, MO).
Statistics. The effects of treatment were analyzed with factorial ANOVAs with Fisher's corrections for multiple tcomparisons. In addition, all responses were tested for significance (i.e., difference from zero) with one-group t-tests. The effects of dose and length of treatment were tested with a multiple regression analysis. P Ͻ 0.05 was considered significant. All statistical calculations were done with StatView version 4.5 (Abacus Concepts, Berkeley, CA).
RESULTS
RPD was measured in ⌬F508 CF mice and their wild-type littermates before and 24 and 48 h after the start of treatment with TMAO. To amplify the CFTRdependent RPD, all measurements were done in the presence of amiloride (to block the Na ϩ -dependent RPD) and with Cl Ϫ -free solutions. The change of perfusion solution from a Cl Ϫ -containing to a Cl Ϫ -free solution (in the presence of amiloride) did not result in significant changes in RPD in any of the treatment groups (average for all groups, Ϫ0.11 Ϯ 0.51 mV; n ϭ 55 mice; P ϭ 0.84 by one-sample t-test). Figure 1A shows representative recordings of the responses to forskolin, and Fig. 1B shows the average responses measured in control and TMAO-treated wild-type mice. Perfusion with forskolin induced a hyperpolarization of RPD, which indicated activation of a Cl Ϫ conductance in the rectal epithelium. In control mice, perfusion with forskolin hyperpolarized RPD by Ϫ6.4 Ϯ 0.79 mV (n ϭ 11). Treatment with TMAO significantly increased the responses to forskolin in normal mice to Ϫ12.6 Ϯ 2.0 mV (n ϭ 7) at 24 h and to Ϫ13.5 Ϯ 2.0 mV (n ϭ 10) at 48 h, which were not different from one another (Fig. 1B) . Figure 1 , C and D, shows representative recordings and the average responses from ⌬F508 CF mice. In untreated CF mice, RPD was not significantly affected by forskolin (Ϫ0.10 Ϯ 0.14 mV; n ϭ 14 mice; not different from zero by one-group t-test). Treatment with TMAO significantly increased the responses to forskolin in ⌬F508 mice to Ϫ1.3 Ϯ 0.38 mV (n ϭ 9) at 24 h and to Ϫ1.0 Ϯ 0.3 mV (n ϭ 7) at 48 h, which were not different from one another (Fig. 1D ). These data show that the treatment of mice with TMAO increased the forskolin-activated RPD in both wild-type and ⌬F508 CF mice.
The effects of dose and length of treatment with TMAO were tested with a multiple regression analysis. In ⌬F508 CF mice, the responses of RPD to forskolin correlated significantly with the administered dose (P ϭ 0.019) but not with length of treatment (P ϭ 0.89). Figure 2 shows the relationship between dosage and forskolin-induced RPD responses, which yielded a slope of Ϫ0.40 Ϯ 0.10 mV ⅐ g Ϫ1 ⅐ kg Ϫ1 . To verify the CFTR dependence of the forskolininduced responses of RPD by TMAO treatment, we Responses in CF mice were significantly smaller than in wild-type mice (P Ͻ 0.0001). TMAO treatment significantly increased ⌬RPD to forskolin after 24 and 48 h in wild-type and CF mice (P Ͻ 0.001). Measurements at 24 and 48 h were not different in both groups (all tested with factorial ANOVA followed by t-tests).
carried out experiments that probe for CFTR by using 1) CFTR knockout mice, 2) the CFTR blocker glibenclamide, and 3) the CFTR activator apigenin. Representative experiments with CFTR knockout mice are shown in Fig. 3 . CFTR knockout [(Ϫ/Ϫ)] mice and their heterozygous littermates were treated with 4 g/kg body wt of TMAO for 24 h. In heterozygotes (Fig. 3A) but not in CFTR(Ϫ/Ϫ) mice (Fig. 3B) , forskolin hyperpolarized the RPD, indicating the lack of a Cl Ϫ conductance in TMAO-treated CFTR(Ϫ/Ϫ) mice. In CFTR(Ϫ/Ϫ) mice, forskolin caused a depolarization of 1.6 Ϯ 1.3 mV (n ϭ 5), which was possibly caused by the activation of K secretion in these mice, similar to that reported for the mouse colon epithelium (8) .
The effect of perfusion of the rectal mucosa with 300 M glibenclamide is shown in Fig. 4 . In wild-type mice, glibenclamide partially (39 Ϯ 16%; n ϭ 3) inhibited the forskolin-stimulated RPD (Fig. 4A) . In TMAO-treated (4 g/kg body wt, 24 h) ⌬F508 CF mice, forskolin hyperpolarized RPD by Ϫ1.9 Ϯ 0.1 mV (n ϭ 3) in this set of experiments, of which glibenclamide inhibited 53 Ϯ 7.8% (i.e., 1.0 Ϯ 0.04 mV; n ϭ 3; Fig. 4B ). The partial block of CFTR by glibenclamide is comparable to its effects in other CFTR-expressing epithelia such as Calu-3 cells (29 Ϯ 5%) in the presence of a mucosal Cl Ϫ -free solution (23) . Partial block of CFTR by glibenclamide in presence of mucosal Cl Ϫ -free solution is consistent with the voltage-dependent blocker affinity of glibenclamide, which has been shown to be reduced when the membrane potential was depolarized (30) .
We also tested the CFTR activator apigenin (21) in TMAO-treated ⌬F508 CF mice (4 g/kg body wt, 24 h). The effect of acute perfusion of apigenin is shown in Fig. 5 . In this set of experiments, perfusion with forskolin hyperpolarized RPD to, on average, Ϫ1.4 Ϯ 0.3 mV (n ϭ 6 mice). The addition of apigenin caused a further hyperpolarization and a total response of Ϫ2.5 Ϯ 0.5 mV (P ϭ 0.036 by paired t-test; Fig. 5B ). For comparison, in untreated CF mice, rectal perfusion with apigenin did not significantly affect RPD (change in RPD ϭ 0.12 Ϯ 0.19 mV; n ϭ 5 mice; not different from 0, P ϭ 0.56; Fig. 5B ).
DISCUSSION
Using ⌬F508 CFTR heterologously expressed in cell cultures, Brown et al. (3) reported that the chemical chaperones glycerol (1.2 M) and TMAO (100 mM) corrected the maturation defect of ⌬F508 CFTR. These investigators measured the TMAO effect by the appearance of the mature, fully glycosylated band C in Western blots of CFTR and by Cl Ϫ efflux in cellular studies. When we initially tested these chemical chaperones in an in vivo mouse model, our goal was to achieve concentrations that were similar to the effective concentrations in the cell culture model used by Brown et al.. We found that it was not possible to achieve adequate serum levels using glycerol without severe toxicity. However, with TMAO given in subcutaneous injections every 8 h over 48 h, it was possible to achieve similar serum concentrations of ϳ50-100 mM with only 50% lethality (1). These high concentrations were necessary to achieve measurable effects in this in vivo study and are similar to the effective TMAO concentration in the cell culture studies (3). Thus the experiments for this study were designed to test the efficacy of this chaperone in correcting the Cl Ϫ defect in CF mice.
The data show that TMAO treatment partially corrected the forskolin-activated Cl Ϫ conductance in CF mouse rectum. In single-channel recordings, the ⌬F508 CFTR mutant expresses a reduced open probability (25-30% of normal value; 9, 11, 19) and the lifetime in Fig. 2 . Dose-dependent effects of TMAO treatment on ⌬RPD to forskolin. E, Before treatment; F, after 24-h treatment; ƒ, after 48-h treatment. bw, Body weight. Data points were taken from the recordings after RPD reached stable values (ϳ10 min after forskolin addition) and represent the numerical average of a 1-min period. ⌬RPD to forskolin in ⌬F508 CF mice correlated with the TMAO dose, resulting in a slope of Ϫ0.40 Ϯ 0.095 mV ⅐ g Ϫ1 ⅐ kg Ϫ1 (P ϭ 0.0003; r ϭ 0.69). There was no significant correlation to length of treatment, i.e., measurements at 24 and 48 h were not different (P ϭ 0.89 by multiple regression analysis). the cell membrane is reduced by ϳ50% (28) . Thus the restoration of normal trafficking of ⌬F508 CFTR can be predicted to yield only a partial recovery (ϳ15%) of the Cl Ϫ conductance found in wild-type cells. We found that treatment with TMAO recovered a response to forskolin of Ϫ1.1 mV in ⌬F508 CF mice, which is ϳ17% of the response in wild-type mice. Although variations in a transepithelial potential difference do not have a direct linear relationship with changes in conductance, the data suggest a significant correction of the trafficking defect of ⌬F508 CFTR. Because some studies support the hypothesis that only a small fraction (5-10%) of normal CFTR-mediated Cl Ϫ conductance is required to ameliorate clinical CF symptoms (10, 20, 27) , it is conceivable that a restoration of ⌬F508 trafficking in humans, similar to the effect observed here in ⌬F508 mice, could be associated with positive clinical effects in patients. However, the main value of these studies is that they constitute a proof of principle that a chemical chaperone can be effective in vivo. Because TMAO itself was associated with severe toxicity (i.e., the compound was used near its half-maximal lethal dose), it cannot be seriously considered for clinical use. Thus the present study demonstrates the feasibility of a pharmacological approach with a chemical chaperone. It also emphasizes the need to develop better compounds, characterized by higher efficiency and lower toxicity.
A second aspect of our work is that treatment with a chemical chaperone combined with a CFTR activator might be beneficial. Several CFTR activators have been previously described (2, 15, 21, 22) . We selected apigenin for this study because of its high affinity and low toxicity. We found that in TMAO-treated ⌬F508 CF mice, the effects on Cl Ϫ -selective potentials were almost doubled after the addition of apigenin (Fig. 5) . Previously, Illek and Fischer (21) reported that apigenin is a potent CFTR activator by increasing the open probability of wild-type CFTR, and apigenin can potentiate in vitro the effect of 4-phenylbutyrate on ⌬F508 CFTR (24) . The present study shows that the combination of a chemical chaperone with a channel activator also exhibits a synergistic effect in vivo.
Clearly, the extraordinarily high concentrations that we employed in this study are likely to have caused various other physiological and cellular effects, such as upregulation of hormones responsible for osmotic homeostasis and induction of cellular stress proteins, possibly including the heat shock proteins (HSPs). Therefore, it may be possible that the effect of TMAO treatment may be indirectly mediated by a response to the osmotic stress. Using the chemical chaperone glycerol (1 M), Brown et al. (3) have shown that treatment of NIH/3T3 mouse fibroblasts with glycerol did not induce expression of the heat-inducible HSP72; however, glycerol treatment supported maturation of recombinant ⌬F508 CFTR. When these cells were further heat stressed, expression of HSP72 was induced in control cells but not in glycerol-treated cells (3) . Similarly, in HeLa cells, heat shock-induced expression of HSP73 was blocked by glycerol (4), and no effects of glycerol on HSP70 mRNA expression were detected in Madin-Darby canine kidney cells (6) . These data show that treatment with the chemical chaperone glycerol did not affect the expression of several HSPs, and the heat-induced expression of HSP did not support ⌬F508 maturation. Thus it appears that the effect of chemical chaperones on ⌬F508 CFTR maturation is not related to the expression of HSPs. Although this has not been tested for TMAO, the proposed common mechanism of action (see below) of both TMAO and glycerol supports the notion that HSPs are not involved in the treatment-induced recovery of ⌬F508 CFTR. To test for side effects of TMAO in vivo in mice, a panel of serum parameters, including electrolytes and liver enzymes, was measured (1). Only minor, insignificant effects on the concentrations of glucose, NaCl, bicarbonate, phosphate, and albumin were detected, and it was concluded that treatment with TMAO did not impair renal, liver, pancreas, or muscle function (1). Thus these previous measurements did not show significant changes in blood chemistry and on cellular stress protein expression. Although an effect of TMAO on other factors (which may mediate ⌬F508 CFTR expression) cannot be ruled out from our study, the simplest explanation of our data is a direct recovery of ⌬F508 trafficking by TMAO.
The in vivo measurement of RPD is determined by the ion selectivity of both the transcellular and paracellular pathways, both of which may have been affected by TMAO treatment, and a contribution of the paracellular pathway cannot be excluded. However, the following observations suggest that the TMAOrecovered RPD is mediated in large part by CFTR activity: 1) stimulation by forskolin in ⌬F508 but not in knockout mice, 2) sensitivity to glibenclamide, and 3) sensitivity to apigenin.
The mechanism of action of chemical chaperones is not totally understood. These molecules may support the formation of a stable conformation of CFTR in the endoplasmic reticulum. They are thought to act through a mechanism of stabilizing protein structures by affecting the degree of hydration and stabilize intramolecular interactions (7, 12, 13) . Interestingly, in our study, TMAO increased the responses to forskolin in both wild-type and ⌬F508 CF mice. This observation is consistent with the hypothesis that only a fraction (25%) of wild-type CFTR trafficks correctly to the cell membrane, whereas the majority of wild-type CFTR and probably all of ⌬F508 CFTR are targeted for degradation by intracellular proteasomes (26, 33, 37) . Thus the stabilization of the CFTR protein in the endoplasmic reticulum by TMAO may increase forskolin-activated RPDs in both normal and CF mice.
In summary, these studies provide evidence that in vivo treatment with TMAO can partially correct the Cl Ϫ conductance defect in ⌬F508 CF mice. Although TMAO is unlikely to be suitable for clinical use, these studies in CF mice provide support for the potential efficacy of a less toxic chemical chaperone for treatment of human CF.
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